Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

How exactly does dantrolene treat malignant hyperthermia when it is inhibiting Ca release just as succinylcholine (the culprit of malignant hyperthermia) is already inhibiting Ca?

April 26, 2017ca culprit dantrolene hyperthermia inhibiting malignant release succinylcholine treat

0

Posted

How exactly does dantrolene treat malignant hyperthermia when it is inhibiting Ca release just as succinylcholine (the culprit of malignant hyperthermia) is already inhibiting Ca?

1 Answer

0

Posted

Malignant Hyperthermia [hyperpyrexia] is an inherited (pharmacogenetic) disorder of skeletal muscle, characterised by a hypermetabolic state, triggered by volatile anaesthetics (ie. halothane) and succinylcholine resulting in a rapid rise in body temp and HR. Intracellular calcium increases up to 500 fold leading to sustained muscle contraction and rigidity. Overall the incidence of MH is about 1:50,000. Dantrolene (DOC) acts by decreasing the release of calcium from the SR.